I usually have a lot to say. I just know when to keep it to myself.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Down and BOARD:
As a new exciting feature of our Poster Of The Week, I've come up with
a splendid new idea.
Down, I'd like you to stay our typical week-and-a-half as our honored poster.
From there on, we'll pick Fridays to name our new poster of the week.
Therefore, the next pick will be on August 03, 2007. It will be up to YOU
to pick the new poster and post their new title on the board.
Then, you can instruct your choice to do the same for the new POTW
named on August 10th, and so on.
I will put a list of the past honored posters in the ibox for everyone to celebrate
and watch. However, this new approach is a great "pass it forward" way to
include your own nominations from your personal perspective.
Hope thats ok with you. You do, after all, pay great attention to detail. :)
That was such a cool thing to say, Down that I've put it as your quote in the ibox. :)
announcing--------THE FAT CATS POSTER OF THE WEEK!------------------
is................DownWithPumpers!!!!!!!!!!!
http://investorshub.advfn.com/boards/profile.asp?User=84632
Way to GO! You've been watched since the first week of naming our posters in
our famous ibox. Then you left for a good week and we're so thrilled you're back.
Your DD since your first post on Fat Cats has been exceptional and your contributions
to our Friday jams are filled with information for Cats new to the stock in question,
and typically the investors of the companies as well.
It's been a long time since a poster has filled their time with remarkable research and DD.
You are certainly an important facet of the respected posters on our board,
that helps create the pool of knowledge when scouting plays.
Thank you for your efforts here. You are an awesome Fat Cat :)
** July 25, 2007
IPKL:
I don't pay enough attention to these subbies, but caught the chart on a scan. (below).
Then I peeked at the board and saw this post (also below) and have zero idea what this poster is referring to.
Anyone care to fill me in here?
I'll pm this post to it's poster, but thought somebody here was
keen to the "countdown". tia.
Posted by: cyclone101
In reply to: None Date:7/24/2007 5:09:29 PM
Post #of 22311
7 DAYS!!!!!!.......GL ALL!!!
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21520421
INCY, clunker. Guess people know that Thursday will be more money gone into research. Hope for some surprises, will check back on this one on Friday. (link back)
nine times out of ten, liz. Or on top of my fridge.....
but thats too high up for me to see-
so i grab a chair,
look on top
and if lucky have found one of the three pairs that I lose every morning.
Poor Serf. I don't know how he makes sense of the mess I give him for the picks, lol
ABAT (eeek! a bat!), rock on little bat
(link back or check http://www.infinitistocks.com on the penny page)
NOTE: AMSC. The PR in the post is for "AMSC". I put "ACMS" and the "ACMS" in the chart link.
If you ever notice the PR ticker not matching the chart ticker, or title of my post........please post
PUT YOUR GLASSES ON - or simply send me a quick PM. Thanks!
I've been doing this a lot lately, lol
AMSC:
Listed here at: 19.58 (by a half blind lady, lol)
Opened at 20.89
nice gains today....link back for morning PR (but not the header or chart)
Chart for AMSC, for PR from this morning:
playing a game called "find my glasses" right now, lol
thanks lizzy- having a good day?
GGBM........weeeeeeeeeeeeeeeeeeeeeeee
(link back to press and chart at bottom of post)
http://www.infinitistocks.com
CAMT awesome day (link back to press and chart at bottom of post)
http://www.infinitistocks.com
ABAT: 2.73 - Advanced Battery Technologies Announces Contract With ZAP, a Leading Provider of Zero Emissions Vehicles
Tuesday July 24, 8:30 am ET
Shares Outstanding: 49.63M
Float: 41.78M
Order for ABAT's Polymer Lithium and Nano Batteries Worth $5.168 Million
HARBIN, CHINA--(MARKET WIRE)--Jul 24, 2007 -- Advanced Battery Technologies, Inc. (OTC BB:ABAT.OB - News) announced today that it has entered into an agreement to supply ZAP with $5.168 million of polymer lithium and nano batteries. U.S.-based ZAP invents, designs, manufactures, and markets personal and commercial zero-emission vehicles for land, water, and air use. Advanced Battery Technologies, Inc. develops, manufactures, and distributes rechargeable polymer-lithium-ion (PLI) batteries.
"We are extremely gratified to receive this substantial order from ZAP. This is our first order from a U.S. company and validates our U.S. targeted marketing efforts," stated Mr. Zhinguo Fu, ABAT Chairman and Chief Executive Officer. "We're excited about the huge opportunity for our products in the U.S., as companies like ZAP proliferate to meet the growing demand for zero-emission vehicles," Mr. Fu concluded.
About Advanced Battery Technologies, Inc.
Founded in September 2002, Advanced Battery Technologies develops, manufactures, and distributes PLI batteries using lithium cobalt oxide anodes to overcome many of the shortcomings associated with other types of rechargeable batteries. ABAT develops PLI batteries for use in electric vehicles, mine lamps, cell phones, notebook computers, and other electronic devices. ABAT maintains R&D and manufacturing facilities in Harbin, China. Additional information about Advanced Battery Technologies is available at www.abat.com.cn.
About ZAP
ZAP has been a leader in advanced transportation technologies since 1994, delivering over 100,000 vehicles to consumers in more than 75 countries. At the forefront of fuel-efficient transportation with new technologies including energy efficient gas systems, hydrogen, electric, fuel cell, ethanol, hybrid and other innovative power systems, ZAP is developing a high-performance crossover SUV electric car concept called ZAP-X engineered by Lotus Engineering. The Company recently launched a new portable energy technology that manages power for mobile electronics from cell phones to laptops. For product, dealer, and investor information, visit http://www.zapworld.com.
Certain statements in this news release may constitute "forward-looking" statements within the meaning of section21E of the Securities and Exchange Act of 1934. The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations. These statements are not, however, guarantees of future performance and actual results may differ materially. Some of the factors that may affect the forward-looking statements in this news release are the availability of licensed personnel to operate pharmacies, the availability of suitable retail locations, and the acceptance of new technologies by the medical profession. Other risk factors are listed in the most recent Annual Report on Form 10-KSB, Quarterly Report on Form 10-QSB, and most recent Registration Statement on Form SB-2 filed with the Securities and Exchange Commission. Such forward-looking statements involve risks and uncertainties, which may cause the actual results, performance, or achievement expressed or implied to differ.
Source: Advanced Battery Technologies, Inc.
http://biz.yahoo.com/iw/070724/0281478.html
CAMT 3.38: Camtek Receives Order for Over Forty AOI Systems
Tuesday July 24, 8:11 am ET
Adopted and Implemented a Cost Reduction Plan
Shares Outstanding: 30.04M
Float: 10.63M
MIGDAL HA'EMEK, Israel, July 24 /PRNewswire-FirstCall/ -- Camtek Ltd. (NASDAQ: CAMT; TASE: CAMT), announced today that it received a multi-million dollar order for automated optical inspection (AOI) systems from a leading PCB manufacturer based in Taiwan.
The order includes forty four of the new 3G family Dragon and Orion AOI systems recently presented to the market. In addition, the order includes upgrading thirty two of existing systems to 3G performance and more than 20 units of new CVR100 verification systems. The new systems will be installed at the customer's new plant in China and the revenues will be recognized during the third and fourth quarters of 2007.
Cliff Young, general manager of Camtek Taiwan, said, "The significance of this order goes far beyond its sheer size. Having won an intensive evaluation against two competitors, the order indicates the value to the customer of our new "3G" lines and the EyeQ technology that powers it. We are proud to be a part of this customer's expansion plan, and expect to continue to support this client in the future."
Rafi Amit, Camtek's CEO, added: "At this time it is also important to emphasize that in addition to the steps taken during the last six months, we have adopted and implemented a cost reduction plan, the effects of which will be fully reflected beginning in the third quarter. These measures have not materially impacted our R&D, sales or customer support capabilities."
About Dragon and Orion "3G" Family
"3G" denotes the new generation of our Dragon and Orion product lines. In addition to enhanced optics and new firmware, "3G" models are powered by Camtek's proprietary EyeQ(TM) technology - a totally new approach to the entire operation of AOI system. EyeQ embeds Camtek's inspection expertise into each system, enabling any operator to achieve top performance without prior experience. But unlike "quick setup" tools that apply one predefined template to any situation, EyeQ optimizes and adapts detection parameters to user preferences for each individual application.
About Camtek
With headquarters in Migdal Ha'Emek Israel, Camtek Ltd., designs, develops, manufactures, and markets automatic optical inspection systems and related products. Camtek's automatic inspection systems are used to enhance both production processes and yield for manufacturers in the printed circuit board industry, the high density interconnect substrate industry and the semiconductor manufacturing and packaging industry. This press release is available at www.camtek.co.il.
This press release may contain projections or other forward-looking statements regarding future events or the future performance of the Company. These statements are only predictions and may change as time passes. We do not assume any obligation to update that information. Actual events or results may differ materially from those projected, including as a result of changing industry and market trends, reduced demand for our products, the timely development of our new products and their adoption by the market, increased competition in the industry, price reductions as well as due to risks identified in the documents filed by the Company with the SEC, which can be accessed at www.sec.gov.
Contact Information
Camtek
Ronit Dulberg, CFO
Tel: +972-4-604-8308
Fax: +972-4-604 8300
Mobile: +972-54-9050776
ronitd@camtek.co.il
IR International
Ehud Helft / Kenny Green
GK International
Tel: (US)+1-866-704-6710
kenny@gk-biz.com
ehud@gk-biz.com
--------------------------------------------------------------------------------
Source: Camtek Ltd
http://biz.yahoo.com/prnews/070724/uktu037.html?.v=2
CAMT 3.38: Camtek Receives Order for Over Forty AOI Systems
Tuesday July 24, 8:11 am ET
Adopted and Implemented a Cost Reduction Plan
Shares Outstanding: 30.04M
Float: 10.63M
MIGDAL HA'EMEK, Israel, July 24 /PRNewswire-FirstCall/ -- Camtek Ltd. (NASDAQ: CAMT; TASE: CAMT), announced today that it received a multi-million dollar order for automated optical inspection (AOI) systems from a leading PCB manufacturer based in Taiwan.
The order includes forty four of the new 3G family Dragon and Orion AOI systems recently presented to the market. In addition, the order includes upgrading thirty two of existing systems to 3G performance and more than 20 units of new CVR100 verification systems. The new systems will be installed at the customer's new plant in China and the revenues will be recognized during the third and fourth quarters of 2007.
Cliff Young, general manager of Camtek Taiwan, said, "The significance of this order goes far beyond its sheer size. Having won an intensive evaluation against two competitors, the order indicates the value to the customer of our new "3G" lines and the EyeQ technology that powers it. We are proud to be a part of this customer's expansion plan, and expect to continue to support this client in the future."
Rafi Amit, Camtek's CEO, added: "At this time it is also important to emphasize that in addition to the steps taken during the last six months, we have adopted and implemented a cost reduction plan, the effects of which will be fully reflected beginning in the third quarter. These measures have not materially impacted our R&D, sales or customer support capabilities."
About Dragon and Orion "3G" Family
"3G" denotes the new generation of our Dragon and Orion product lines. In addition to enhanced optics and new firmware, "3G" models are powered by Camtek's proprietary EyeQ(TM) technology - a totally new approach to the entire operation of AOI system. EyeQ embeds Camtek's inspection expertise into each system, enabling any operator to achieve top performance without prior experience. But unlike "quick setup" tools that apply one predefined template to any situation, EyeQ optimizes and adapts detection parameters to user preferences for each individual application.
About Camtek
With headquarters in Migdal Ha'Emek Israel, Camtek Ltd., designs, develops, manufactures, and markets automatic optical inspection systems and related products. Camtek's automatic inspection systems are used to enhance both production processes and yield for manufacturers in the printed circuit board industry, the high density interconnect substrate industry and the semiconductor manufacturing and packaging industry. This press release is available at www.camtek.co.il.
This press release may contain projections or other forward-looking statements regarding future events or the future performance of the Company. These statements are only predictions and may change as time passes. We do not assume any obligation to update that information. Actual events or results may differ materially from those projected, including as a result of changing industry and market trends, reduced demand for our products, the timely development of our new products and their adoption by the market, increased competition in the industry, price reductions as well as due to risks identified in the documents filed by the Company with the SEC, which can be accessed at www.sec.gov.
Contact Information
Camtek
Ronit Dulberg, CFO
Tel: +972-4-604-8308
Fax: +972-4-604 8300
Mobile: +972-54-9050776
ronitd@camtek.co.il
IR International
Ehud Helft / Kenny Green
GK International
Tel: (US)+1-866-704-6710
kenny@gk-biz.com
ehud@gk-biz.com
--------------------------------------------------------------------------------
Source: Camtek Ltd
http://biz.yahoo.com/prnews/070724/uktu037.html?.v=2
INCY 5.61 (*caution, fins out Thurs): Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients
Tuesday July 24, 6:00 am ET
Results Suggest that INCB9471 Has the Potential to Provide Advantages over Other CCR5 Antagonists in Development
SYDNEY, Australia--(BUSINESS WIRE)--Results from a 14-day Phase IIa clinical trial, presented today at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, demonstrate that INCB9471, an investigational drug for the treatment of HIV-1, the retrovirus that causes the acquired immunodeficiency syndrome, AIDS, provided a significant decline in viral load when used as monotherapy in 19 HIV-infected subjects, including ten treatment-naive and nine treatment-experienced patients not currently on antiviral therapies.
INCB9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. CCR5 antagonists work through a different mechanism of action than currently marketed oral antiviral drugs. Rather than fighting HIV inside a patient's white blood cells, CCR5 antagonists prevent the virus from entering uninfected cells by blocking its predominant entry route, the CCR5 co-receptor.
Results from this 14-day placebo-controlled Phase IIa study, which involved a total of 23 HIV-infected patients, demonstrated that the 200 mg once-daily dose of INCB9471 provided potent and prolonged antiviral effects in HIV patients with R5-tropic virus. Patients receiving INCB9471 achieved a mean 1.72 log10 viral load drop at day 14. The nadir in mean viral load decline was 1.81 log10 and occurred at day 16. Consistent with the long half-life of INCB9471 of 60 hours, at day 28, two weeks after their last dose, treated patients continued to show evidence of viral suppression with a mean 0.81 log10 reduction in viral load relative to baseline. INCB9471 was also extremely well-tolerated in this initial Phase IIa trial.
Calvin Cohen, M.D., M.S., the presenting principal clinical investigator and Research Director for both Harvard Vanguard Medical Associates and Community Research Initiative of New England, stated, "With its impressive and sustained antiviral effects, its ability to be taken as a once-a-day therapy without ritonavir-boosting and its potential to be combined with other once-daily antiviral therapies, INCB9471 has the potential to provide clinically relevant advantages over other CCR5 antagonists in development."
Dr. Cohen added, "I believe these data, along with data from other CCR5 antagonists, strongly suggest that this new class of drugs has the potential to provide an important advance for how we treat HIV patients."
Based on the results from this study, further clinical development of INCB9471 is warranted. Additional once-daily doses of INCB9471 are currently being evaluated to support initiation of two six-month Phase IIb studies.
About this Study
The Phase IIa placebo-controlled trial was designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of 200 mg once-daily dose of INCB9471 as monotherapy in HIV-infected subjects harboring R5-tropic virus. HIV enters a cell by first binding to the CD4 receptor. After a conformational change, it then binds to either the CCR5 (R5) or CXCR4 (X4) co-receptor. The study involved 23 HIV-infected patients who were either treatment-naive or treatment-experienced who had not received antiretroviral treatments for a minimum of three months. Nineteen of the subjects received INCB9471, ten were treatment-naive and nine were treatment-experienced; four patients received placebo, two were treatment-naive and two were treatment-experienced.
Summary of Findings
Safety: INCB9471 was safe and well tolerated with no clinically significant chemistry, hematology or ECG changes as compared to placebo patients.
Pharmacokinetics: INCB9471 exhibited a long plasma half-life of 60 hours that is expected to provide more effective suppression of the virus even if patients occasionally miss a dose.
Efficacy: Subjects receiving INCB9471 showed rapid and prolonged reduction in viral load with a mean maximal decline of 1.81 log10 at day 16. Consistent with the long plasma half-life of INCB9471, viral load continued to be suppressed well beyond the 14-day dosing period with a mean 0.81 log10 decline in viral load observed at day 28. The HIV treatment-naive and HIV treatment-experienced patients who received INCB9471 had comparable reductions in viral load.
CD4+ cell counts were stable or slightly increased over the 14-day course of therapy in all treated patients.
Tropism: Tropism assays were conducted at screening, baseline, day 7 or day 14, and at day 28. Two of the 19 treated patients showed a change in tropism from pure R5 utilizing virus to a mixture of R5 and X4 utilizing virus. Clonal tropism and sequencing data suggest that these dual/mixed virus populations likely reflect pre-existing viral variants. Both patients showed reversion to R5 tropic virus after day 28. These results are similar to what has been observed with other CCR5 antagonists.
A copy of the presentation can be accessed using the following link: http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-presentations
About Incyte
Incyte Corporation (NASDAQ:INCY - News) is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Incyte has a pipeline with programs in HIV, diabetes, oncology and inflammation. For additional information on Incyte, visit the Company's web site at www.incyte.com.
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to the potential for INCB9471 to be combined with other once-daily antiviral therapies and to provide clinically relevant advantages over other CCR5 antagonists in development, the potential for the new class of drugs to provide an important advance for how HIV patients are treated, expectations regarding the initiation Phase IIb studies of INCB9471, and the efficacy and potential benefits of INCB9471, are all forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the high degree of risk associated with drug development and clinical trials, results of further research and development, the impact of competition and of technological advances and the ability of Incyte to compete against parties with greater financial or other resources, Incyte's ability to enroll a sufficient number of patients for its clinical trials, and other risks detailed from time to time in Incyte's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. Incyte disclaims any intent or obligation to update these forward-looking statements.
Contact:
Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations/Corporate
Communications
302-498-6944
--------------------------------------------------------------------------------
Source: Incyte Corporation
Email Story
Set News Alert
Print Story
http://biz.yahoo.com/bw/070724/20070724005189.html?.v=1
OTIV 5.89 Garanti Bank of Turkey Chose OTI Solutions for Its Contactless Payments Program
Tuesday July 24, 4:30 am ET
- After Comprehensive Examinations Garanti Bank Chose to Launch New Form Factors and Expand Merchant Base Using OTI Products
- First Deliveries are About Three Quarters of a Million Dollars
Shares Outstanding: 18.90M
Float: 12.21M
FORT LEE, N.J. and ISTANBUL, Turkey, July 24 /PRNewswire-FirstCall/ -- On Track Innovations Ltd. (OTI) (Nasdaq: OTIV - News), a global leader in contactless microprocessor-based smart card solutions for homeland security, payments, petroleum payments and other applications, together with Garanti Payment Systems , a company that is the fastest and most efficient product developer for the Turkish credit card industry and 99.99% owned by Garanti Bank, today announced that Garanti Payment Systems has made a strategic decision and chose OTI to supply its Contactless solutions for the Turkish Market. As a first kickoff of the contactless project by Garanti Bank, deliveries are about three quarters of a million dollars. Garanti Bank has extensive plans to implement its contactless solutions to its broad customer base.
Garanti Payment Systems, established in 1999 as the single service point for Garanti's credit card business, is the company behind the fastest growing and most innovative products in the Turkish credit card business. As REHA EMEKLI, Executive Vice President of Garanti Payment Systems explains, the products are used by Garanti Bank for its 'Tap & Go(TM)' program. The program uses MasterCard PayPass technology and is offered to the Bank's Bonus cardholders under the Bonus Trink. The readers are installed in areas of Istanbul while the PayPass Cards, Smart Stickers, Key Fobs and watches are offered to "Bonus Trink" members.
OTI provides its Saturn 6000 contactless reader - an exceptionally fast reader with built in encryption capabilities developed to address the specific needs of the global contactless markets and the enhanced security required in EMV markets. The Saturn 6000 is the first reader to be certified for EMV and ISO 14443 PayPass version 1.1 required by MasterCard starting this year.
The orders also include inlays for MasterCard PayPass programs, watches, key fobs and SMART Stickers, a new payment form factor, approved by MasterCard for its PayPass program, which allows to upgrade any mobile phones to become contactless payment devices.
Turkey is one of the first countries in Europe to implement PayPass contactless technologies and Garanti Bank is the first bank in Turkey to introduce this technology.
REHA EMEKLI, Executive Vice President of Garanti Payment Systems, said: "We are fastest and most innovative payment system company and OTI's experience provides a reliable and cost-effective way to bring contactless solutions to our market. We will continue our contactless way by issuing any form factor products such as inlays, stickers, key fobs, wristwatches, including reader solutions. This will make our Bonus Trink programme stronger and help us differentiate ourselves in Turkey's highly competitive payments market."
Oded Bashan, Chairman, President and CEO of OTI commented: "The fact that Garanti Bank of Turkey chose OTI as its solution provider for all contactless payment activity points to the superiority of OTI solutions and further validates OTI's product readiness in the contactless EMV markets."
OTI is proud to be chosen by Garanti Bank which plays a vital role in delivering innovative solutions to the Turkish Market.
About Garanti Bank
With $36 billion asset size as of December 31, 2006. Garanti provides retail, commercial, corporate and private banking services to over 6.2 million customers. As of December 2006, it operates 487 domestic branches, five foreign branches (in Luxembourg, Malta and Northern Cyprus (3), four international representative offices (in Moscow, London, Dusseldorf and Shangai), 1,455 ATMs, a call center and an internet bank utilizing its state- of-the-art technology and focusing in customer satisfaction.
About OTI
Established in 1990, OTI (Nasdaq: OTIV - News) designs, develops and markets secure contactless microprocessor-based smart card technology to address the needs of a wide variety of markets. Applications developed by OTI include product solutions for petroleum payment systems, homeland security solutions, electronic passports and IDs, payments, mass transit ticketing, parking, loyalty programs and secure campuses. OTI has a global network of regional offices to market and support its products. The company was awarded the Frost & Sullivan 2005 and 2006 Company of the Year Award in the field of smart cards.
For more information on Garanti Bank, visit www.garanti.com.tr
For more information on OTI, visit www.otiglobal.com.
Safe Harbor for Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Whenever we use words such as "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions, we are making forward-looking statements. Because such statements deal with future events and are based on OTI's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of OTI could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding our goals, beliefs, future growth strategies, objectives, plans or current expectations, such as those regarding the performance of Garanti's programmes and the improvements that OTI's contactless solutions will lead to, and expected revenues therefrom. Forward-looking statements could be impacted by market acceptance of new and existing products and our ability to execute production on orders, as well as the other risk factors discussed in OTI's Annual Report on Form 20-F for the year ended December 31, 2006, which is on file with the Securities and Exchange Commission. Although OTI believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be achieved. Except as otherwise required by law, OTI disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
OTI Contact: Investor Relations
Galit Mendelson Miri Segal
Director of Corporate Communications Strategic Growth International
201 944 5200 ext. 111 212 838 1444
galit@otiglobal.com msegal@sgi-ir.com
--------------------------------------------------------------------------------
Source: On Track Innovations Ltd.
http://biz.yahoo.com/prnews/070724/nytu060.html?.v=101
AMCS (cls @ 19.58 - moving PM): AMSC Receives New $70 Million Order from China's Sinovel Wind
Tuesday July 24, 7:30 am ET
-- Wind Turbine Electrical System Order Required for Sinovel's Expanded Manufacturing of 1.5 Megawatt Wind Energy Systems in 2008
-- Sinovel Continues Rapid Growth to Meet China's Demand for Zero-Emission, Wind Generated Electricity
Shares Outstanding: 35.67M
Float: 31.86M
WESTBOROUGH, Mass.--(BUSINESS WIRE)--American Superconductor Corporation (NASDAQ: AMSC - News), a leading energy technologies company, today announced that it has received a follow-on $70 million order for wind turbine electrical systems from Beijing-based Sinovel Wind Corporation Limited. The order calls for AMSC's wholly-owned subsidiary, AMSC Windtec, to ship the customized electrical systems to Sinovel in 2008 for use in Sinovel's 1.5 megawatt (MW) wind energy systems. AMSC Windtec turbine electrical systems provide reliable, high-performance wind turbine operation by controlling power flows, regulating voltage and controlling the pitch of wind turbine blades to maximize efficiency.
"The wind power industry is stronger than ever in China, and Sinovel is doing everything in its power to satisfy the increasing demand for environmentally friendly wind energy systems," said Han Junliang, Chairman and President of Sinovel. "AMSC Windtec has been - and will continue to be - a valued ally in our drive to become a leading wind energy system manufacturer in China and around the world."
In March 2007, AMSC announced that it had signed a contract with Sinovel under which AMSC Windtec and Sinovel will jointly develop 3 MW and 5 MW wind energy systems for which Sinovel has global intellectual property rights. Sinovel plans to market and sell these wind energy systems worldwide. Sinovel is developing this capability to meet the growing worldwide demand for higher power ratings per wind energy system for both onshore and offshore wind farms. Sinovel currently plans to install a 3 MW prototype by the end of 2008 and the first 5 MW prototype before 2010. AMSC is expected to become the qualified electrical system supplier for Sinovel's future 3 MW and 5 MW wind energy systems.
"Sinovel is one the most progressive and green energy companies in the world today and has quickly established itself as a top player in China's wind market," said Greg Yurek, founder and chief executive officer of AMSC. "China's appetite for electricity continues to grow in parallel to its rapidly growing economy. The Sinovel-AMSC team is addressing this challenge with state-of-the-art technology that will help meet this demand in an economical, environmentally friendly way."
In calendar year 2006, Sinovel manufactured more than 100 wind energy systems rated at 1.5 MW each. According to the Sinovel's current plans, this number will exceed 500 systems in 2007. The Global Wind Energy Council estimates that approximately 1,347 MW of wind capacity was installed in all of China in 2006 and expects this figure to grow to 8000 MW by 2010.
About Sinovel
Sinovel Wind Co., Ltd is an industrial company that is engaged in developing, engineering and marketing high tech wind energy systems. The company is headquartered in Beijing and its major manufacturing base is located in Dalia, China. The company is in the process of opening new manufacturing plants in North China and Jiangsu.
About AMSC
AMSC (American Superconductor Corporation - NASDAQ: AMSC) is a leading energy technologies company, offering an array of solutions based on two proprietary technologies: programmable power electronic converters and high temperature superconductor (HTS) wires. The company's products, services and system-level solutions enable cleaner, more efficient and more reliable generation, delivery and use of electric power. AMSC is a leader in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world's principal supplier of HTS wire, the company is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, Secure Super Grids(TM), motors, generators, and advanced transportation and defense systems. AMSC also provides utility and industrial customers worldwide with voltage regulation systems that dramatically enhance power grid capacity, reliability and security, as well as industrial productivity. The company's technologies are protected by a broad and deep intellectual property portfolio consisting of hundreds of patents and licenses worldwide. More information is available at www.amsc.com.
American Superconductor and design, Revolutionizing the Way the World Uses Electricity, AMSC, Powered by AMSC, SuperVAR, D-VAR, DVC, PQ-IVR, PowerModule, PQ-SVC, Secure Super Grids, Windtec and SuperGEAR are trademarks or registered trademarks of American Superconductor Corporation or its subsidiaries.
Any statements in this release about future expectations, plans and prospects for the company, including our expectations regarding the future financial performance of the company and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include: uncertainties regarding the company's ability to obtain anticipated funding from corporate and government contracts, to successfully develop, manufacture and market commercial products, and to secure anticipated orders; the risk that a robust market may not develop for the company's products; the risk that strategic alliances and other contracts may be terminated; the risk that certain technologies utilized by the company will infringe intellectual property rights of others; and the competition encountered by the company. Reference is made to these and other factors discussed in the "Risk Factors" section of the company's most recent quarterly or annual report filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date of this release. While the company anticipates that subsequent events and developments may cause the company's views to change, the company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date this press release is issued.
Contact:
Jason Fredette
Director of Investor & Media Relations
American Superconductor Corporation (NASDAQ: AMSC - News)
508-621-4177
jfredette@amsc.com
--------------------------------------------------------------------------------
Source: American Superconductor Corporation
http://biz.yahoo.com/bw/070724/20070724005233.html?.v=1
FSRL.OB 13.00 (thinly traded, near bott of chart) First Reliance Announces 2nd Quarter Net Income of $907,708 - Up 10.30%
Tuesday July 24, 7:00 am ET
FLORENCE, S.C., July 24 /PRNewswire-FirstCall/ -- First Reliance Bancshares, Inc., (OTC Bulletin Board: FSRL - News), the holding company for First Reliance Bank, today announced 2nd quarter 2007 unaudited pre-tax income of $1.3 million, an increase of $108,783, or 9.32%, compared to $1,167,411 reported in the second quarter of 2006.
Unaudited net income increased 10.30%, to $907,708, as compared to $822,916 reported in the prior-year period. Earnings benefited from strong growth in both net interest income and non-interest income. Specifically, net interest income increased 6.56% to $4.7 million in the second quarter of 2007, while non-interest income increased by 13.65% to $1.4 million. Basic earnings per share grew 8.33%, to $0.26 over the $0.24 reported in the prior year
Net Income for the six months ended June 30, 2007 grew 15.63% to $1.6 million, or $0.45 per diluted share, compared to $1.4 million, or $0.39 per diluted share, for the second quarter of 2006. As was the case with the quarterly results, the higher profitability was driven primarily by higher net interest income, which increased 7.96%, and noninterest income, which increased 19.43%.
As of June 30, 2007, total assets were $509.5 million, an increase of $76.4 million or 17.63%, over the $433.1 million reported for June 30, 2006. Loans increased 15.85% to $399.9 million, funded primarily by growth in deposits. Deposits increased to $424.8 million, up 20% from $353.9 million reported the prior year period.
"I am excited to announce that this quarter marks a milestone of approximately $510M in assets," commented Rick Saunders, President & CEO. "We anticipate strong growth throughout the remaining 2 quarters of 2007 due much to our new Regional Headquarters in Lexington, SC and our new branch in Mt. Pleasant, SC. Both buildings, state-of-the-art in architecture and design, are a direct extension of our promise to remain Easy To Do Business With(TM). To guarantee our customers a convenient banking experience, these new buildings will operate under our 8-8 Mon.-Sat. banking hours, which are currently available at all of our Florence locations and will be a standard going forward. Grand opening celebration plans will be announced during the 3rd quarter of 2007."
"To achieve our vision of becoming 'The largest and most profitable bank in South Carolina', our focus will continue to remain on growing our core services households and increasing our customer retention rate. Our current customer retention rate has grown to over 93%. We believe that this is a direct result of our commitment to provide convenient products and excellent customer service. Our efforts were recently rewarded when our customers awarded us with a customer loyalty rating of 86.10%," Saunders concluded.
First Reliance Bank, founded in 1999, has assets of approximately $510 million, and employs 160 highly talented associates. The bank serves the Upstate, Midlands, Piedmont, Low Country, Grand Strand, and Pee Dee regions of South Carolina. The bank has been recognized for its success including being the only company ever to be named to The Top 25 Fastest Growing Companies(TM) in South Carolina four times including 2002, 2004, 2005, and 2006 (SC Chamber/Elliott Davis. In June 2007, the bank was added to the Palmetto 25, a list of S.C.'s largest publicly held companies. In 2006, the bank was also recognized as one of the Top 15 Best Places to Work in South Carolina by the SC Chamber of Commerce. First Reliance Bank offers Totally FREE Checking, Totally FREE Business, FREE Coin Machines, a Nationwide NO FEE ATM Network, and a 5 Way Mortgage Service Promise. It also offers 8-8 Mon.-Sat. Extended Hours in all of their Florence locations. Its Easy to Do Business With(TM) standard has earned the young bank a customer satisfaction rating of 93% (Performance Solutions-May 2007-Audited). First Reliance Bank is traded as FSRL.OB.
This press release contains forward-looking statements about branch openings within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events.
Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward- looking statements can be guaranteed. Our actual results may vary materially, and there are no guarantees about the performance of our stock.
We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future results or otherwise. You are advised, however, to consult any future disclosures we make on related subjects in our reports to the SEC.
Contact Jeffrey A. Paolucci, Senior Vice President and Chief Financial
Officer, (843) 674-3250
First Reliance Bancshares, Inc.
Consolidated Reports of Income
Three Three
Six Months Six Months Months Months
Ended Ended Ended Ended
June 30, June 30, June 30, June 30,
2007 2006 2007 2006
(Unaudited) (Unaudited) (Unaudited)(Unaudited)
Interest Income
Loans and Fees 16,510,892 13,479,849 8,618,219 7,082,161
Investment Securities
Taxable 446,076 530,540 211,742 260,191
Tax exempt 352,957 314,908 182,816 162,507
Federal funds sold 336,410 275,795 257,751 97,924
Other interest income 87,880 59,153 47,575 33,135
Total 17,734,215 14,660,245 9,318,103 7,635,918
Interest Expense
Time deposits $100,000
and over 3,152,637 2,127,855 1,760,167 1,067,676
Other deposits 4,604,489 3,372,780 2,416,821 1,828,021
Other interest expense 923,937 773,699 476,644 362,979
Total 8,681,063 6,274,334 4,653,632 3,258,676
Net Interest Income 9,053,152 8,385,911 4,664,471 4,377,242
Provision for loan losses 460,436 690,786 325,202 440,501
Net Interest Income after
provision 8,592,716 7,695,125 4,339,269 3,936,741
Noninterest Income
Service charges on
deposit accounts 908,437 774,587 465,767 410,208
Gain on sale of
mortgage loans 1,116,131 939,181 645,889 580,731
Brokerage fees 85,869 59,775 45,009 28,310
Credit life insurance
commissions 4,606 10,608 1,307 4,179
Other charges, commissions
and fees 162,788 125,874 88,325 66,108
Gain on sale of securities
available for sale 5,996 - 4,975 -
Gain on sale of other
real estate 20,374 17,657 11,009 17,657
Gain on sale of
fixed assets 16,104 - 1,689 -
Other 296,606 263,541 159,756 145,575
Total 2,616,911 2,191,223 1,423,726 1,252,768
Noninterest Expense
Salaries and benefits 5,227,430 4,499,706 2,631,655 2,259,071
Occupancy 655,892 561,588 318,496 272,602
Furniture and
equipment related 419,763 359,273 229,102 196,695
Other operating 2,688,958 2,486,816 1,307,548 1,293,730
Total 8,992,043 7,907,383 4,486,801 4,022,098
Income before tax 2,217,584 1,978,965 1,276,194 1,167,411
Income tax expense 602,669 582,346 368,486 344,495
Net Income 1,614,915 1,396,619 907,708 822,916
Basic earnings per share 0.47 0.41 0.26 0.24
Diluted earnings per share 0.45 0.39 0.26 0.23
First Reliance Bancshares, Inc.
Balance Sheet
June 30 June 30 December 31
2007 2006 2006
(Unaudited) (Unaudited) (Audited)
Assets:
Cash and Cash Equivalents
Cash and Due From Banks 7,996,670 10,072,241 17,328,075
Federal funds sold 23,601,000 - 14,135,000
Total cash and cash
equivalents 31,597,670 10,072,241 31,463,075
Investment securities
Securities available for sale 34,412,589 36,101,846 35,931,271
Nonmarketable equity securities 1,995,400 2,473,850 2,187,600
Investment in trust 310,000 310,000 310,000
Total investment securities 36,717,989 38,885,696 - 38,428,871
Loans held for sale 6,472,908 12,336,366 6,632,010
Loans receivable 404,386,897 349,035,226 353,491,036
Less allowance for loan losses (4,458,077) (3,831,630) (4,001,881)
Loans, net 399,928,820 345,203,596 349,489,155
Premises, furniture, and
equipment, net 17,862,726 11,285,542 13,770,135
Accrued interest receivable 2,421,681 2,138,115 2,464,531
Other real estate owned 855,599 1,166,985 1,386,380
Cash surrender value life
insurance 10,335,086 9,910,831 10,134,036
Other assets 3,321,054 2,133,385 2,442,529
Total Assets 509,513,533 433,132,757 456,210,722
Liabilities:
Deposits:
Noninterest bearing
transaction accounts 45,156,803 46,021,304 42,107,434
Interest bearing
transaction accounts 38,442,293 25,316,061 33,243,099
Savings 77,475,956 89,859,516 78,831,730
Time deposits $100,000
and over 147,175,381 104,737,742 111,991,864
Other time deposits 116,503,199 87,949,894 106,763,956
Total deposits 424,753,632 353,884,517 372,938,083
Securities sold under agreements
to repurchase 11,130,839 5,278,809 8,120,014
Advances from Federal Home
Loan Bank 26,000,000 29,800,000 28,500,000
Fed Funds Purchased - 955,000 -
Junior subordinated debentures 10,310,000 10,310,000 10,310,000
Accrued interest payable 780,407 420,874 766,276
Other liabilities 821,571 1,087,928 1,483,086
Total Liabilities 473,796,449 401,737,128 422,117,459
Shareholders' Equity:
Common Stock 34,845 34,064 34,249
Capital Surplus 25,776,154 24,984,291 25,257,814
Restricted Stock (142,528) (83,456) (66,131)
Retained Earnings 10,472,671 7,008,467 8,857,755
Accumulated other
comprehensive income (424,058) (547,737) 9,576
Total Shareholders Equity 35,717,084 31,395,629 34,093,263
Total Liabilities and
Shareholders Equity 509,513,533 433,132,757 456,210,722
--------------------------------------------------------------------------------
Source: First Reliance Bancshares, Inc.
http://biz.yahoo.com/prnews/070724/cltu017a.html?.v=2
GGBM: (cls at 4.85 / up PM) GigaBeam Announces Expansion of Global Reach with Repeat Purchase Order From Key South African Reseller
Tuesday July 24, 3:30 am ET
Order Flow Adds to Global Footprint, Augments Growing Revenues and Further Validates Company's High-Growth Business Model
Shares Outstanding: 6.55M
Float: 3.59M
DURHAM, N.C.--(BUSINESS WIRE)--GigaBeam Corporation (NASDAQ:GGBM - News), deploying market disruptive "wireless fiber optics" technology to economic centers across the globe, announced today that it has received an order for four additional WiFiber® wireless broadband links from its South African reseller InnovatIF Telecoms, a major South African distributor and systems integrator of WiFi, WiMax and proprietary technology solutions. The order further validates GigaBeam's aggressive commercialization strategy to penetrate major metropolitan areas with next generation wireless technology able to bypass existing telecom infrastructure at speeds equal to 1000 DSL lines.
"We view South African as an emerging market for GigaBeam technology and see this follow on order as clear evidence that we are gaining momentum in the region," said Louis Slaughter, Chairman and Chief Executive Officer of GigaBeam. "GigaBeam is firmly committed to expanding our global footprint with strong local partners such as InnovatIF. We look forward to additional orders from this partner in the near future as we continue to strengthen our overriding mission of building shareholder value."
South Africa represents an important market for GigaBeam. Given the costs and challenges of delivering seamless connections through terrestrial fiber in the region, GigaBeam's WiFiber® technology provides robust and cost-effective wireless fiber products and solutions to meet the growing demand.
GigaBeam's WiFiber® technology is similar to terrestrial fiber in terms of speed and reliability. WiFiber® has a substantial advantage over terrestrial fiber because it can be rapidly deployed and costs significantly less to deploy than terrestrial fiber. Terrestrial fiber can take months to deploy and also require significant regulatory and environmental approvals prior to installation.
Today's announcement further advances GigaBeam's significant global reach with recently announced orders in several US regions, the Middle East, Europe and Africa.
The Company has implemented an aggressive commercialization strategy to expand into every major metropolitan area around the world.
GigaBeam's partner InnovatIF Telecoms has identified a niche in the African telecommunications market for a "one stop" wireless and communication "Solution Provider". The InnovatIF Telecoms paradigm continuously adapts to business, making it responsive to the global telecommunications infrastructure, therefore strategically responding to the ever-evolving market of international telecommunications.
GigaBeam WiFiber products operate in the 71-76 GHz and 81-86 GHz upper millimeter wave spectrum bands. The Federal Communications Commission and the European Conference of Postal and Telecommunications Administrations (CEPT) and certain other countries for licensed wireless commercial use have authorized this portion of the spectrum. GigaBeam's founders pioneered use of these frequency bands for commercial use.
About GigaBeam Corporation
GigaBeam's WiFiber® product ushers in a new era of communications by allowing customers to bypass the restrictive telecom oligopoly and connect directly to any city's fiber optics hub or Point-of-Presence (POP). The disruptive impact of an easily deployable, low cost alternative to fiber optics cables is difficult to overestimate, especially since WiFiber's point-to-point high-speed units transmit data via the highest approved radio frequency at speeds equal to 641 T1 lines or 1000 DSL lines.
Current GigaBeam partners and customers include Google, Verizon, ING, Sprint, The Department of Defense, as well as several cities and universities such as San Francisco and Boston University. The Company has implemented an aggressive commercialization strategy to expand into major metropolitan areas around the world.
GigaBeam's visionary management team is fully committed to augmenting current revenues through a network of authorized dealers and resellers across North America, South America, Europe, Africa, the Middle East, India and Asia that have local expertise and established contacts. In short, GigaBeam offers a truly unique investment opportunity with market disruptive wireless technology, a pioneering management team and a worldwide network dedicated to penetrating major metropolitan markets around the globe.
To learn more about GigaBeam's revolutionary wireless technology, please visit www.gigabeam.com/.
For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/gigabeam .
To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/gigabeam/quote.html .
To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/gigabeam/factsheet.html .
Safe Harbor Statement
Statements in this press release regarding GigaBeam's products, services, capabilities, performance, opportunities, development and business outlook that are forward-looking involve and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond GigaBeam's control and difficult to predict, and could cause actual results to differ materially from these anticipated, expressed or forecasted in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: limited capital resources and continued dependence of our operations on additional financing, limited operating history, difficulties in distinguishing GigaBeam's products and services, ability to manufacture and deploy GigaBeam's products, lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, availability of raw materials, subassemblies and components, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the telecommunications industry and the global economy, intense competition in the telecommunications equipment industry and resulting impact on pricing and general financial performance, compliance with federal and state regulatory requirements, timing, availability and success of new technology and product introductions and the other factors discussed in GigaBeam's filings with the Securities and Exchange Commission.
Contact:
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com
--------------------------------------------------------------------------------
Source: GigaBeam Corporation
ACPW- 1.95 Active Power Receives Multimillion Dollar Order for 7.6 Megawatts of Mission Critical Power Systems
Tuesday July 24, 3:00 am ET
European Customer Selects Mobile Data Center Power Protection Solution
Shares Outstanding: 50.10M
Float: 39.43M
AUSTIN, Texas--(BUSINESS WIRE)--Active Power, Inc. (NASDAQ:ACPW - News), inventor and manufacturer of the most reliable and energy-efficient critical power systems in the world, today announced a multimillion dollar order from a blue-chip European-based customer for Containerized Mobile Power systems delivering a total of 7.6 Megawatts (MW) of power. Each Diesel Uninterruptible Power Supply (UPS) system contains Active Power's 1500iC flywheel-based UPS systems, switchgear and 1.9 MW diesel generators. All of these components will be housed in acoustic containers for flexible mobile deployment. The packaging includes fuel tanks, cable deployment systems and redundant engine-starting systems integrating Active Power's GenSTART(TM) module. Installation is scheduled for later this year.
Active Power's 1500iC system features a fully scalable and modular design that can easily be expanded for increased capacity or redundancy. The system offers clients a more cost-effective and flexible solution over that of competing technologies.
"This solution was a perfect fit for our customer requirements," said Jim Murphy, vice president for Europe, Middle East, Africa and Asia Pacific for Active Power. "The modularity of our extensively field-proven units, their inherent space efficiency and operating temperature range played a big factor in the customer's decision-making process and the selection of Active Power. We are the only supplier that can integrate UPS redundancy with a single engine and eliminate the common failure points of Diesel UPS solutions in this size of package. We are delighted our units will be protecting one of the world's largest data processing operators."
Active Power offers best-in-class solutions meeting high power demands in all types of mission-critical applications including data centers, airports, healthcare facilities, manufacturing plants, broadcast stations and military installations. The company has shipped more than 1,600 flywheels in systems delivering more than 400 MW of power to customers worldwide. Active Power systems operate at efficiency levels of up to 98 percent, resulting in lower energy consumption and a real bottom-line impact to energy costs for the end user. In addition, the systems have a 20-year design life with absolutely no degradation in service.
About Active Power
Active Power (NASDAQ:ACPW - News) provides efficient, reliable and green critical power solutions and uninterruptible power supply (UPS) systems to enable business continuity in the event of power disturbances. Founded in 1992, Active Power's flywheel-based UPS systems protect critical operations in data centers, healthcare facilities, manufacturing plants, broadcast stations and governmental agencies in more than 40 countries. Active Power also offers CoolAir, the only solution that provides both backup power and backup cooling. With expert power system engineers and worldwide services and support, Active Power ensures organizations have the power to perform. For more information, please visit www.activepower.com.
Cautionary Note Regarding Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Any forward-looking statements and all other statements that may be made in this news release that are not historical facts are subject to a number of risks and uncertainties, and actual results may differ materially. Specific risks include delays in new product development, product performance and quality issues and the acceptance of our current and new products by the power quality market. Please refer to Active Power filings with the Securities and Exchange Commission for more information on the risk factors that could cause actual results to differ.
Active Power, the Active Power logo, and CleanSource are registered trademarks of, and CoolAir is a trademark of Active Power, Inc. All other trademarks are the properties of their respective companies.
Contact:
Active Power, Inc., Austin
Investor Contact:
John Penver, 512-744-9234
Chief Financial Officer
jpenver@activepower.com
or
Media Contact:
Lee Higgins, 512-744-9488
Public Relations Manager
lhiggins@activepower.com
--------------------------------------------------------------------------------
Source: Active Power, Inc.
http://biz.yahoo.com/bw/070724/20070724005376.html?.v=1
SGR 59.50: Westinghouse, Shaw Group Sign Landmark Contracts to Provide Four AP1000 Nuclear Power Plants in China
Tuesday July 24, 6:36 am ET
- First ever deployment of advanced U.S. nuclear technology there
- Plants are safest, most efficient and economical available worldwide
Shares Outstanding: 80.76M
Float: 74.35M
BEIJING, July 24 /PRNewswire/ -- Westinghouse Electric Company LLC and its consortium partner, The Shaw Group, Inc., (NYSE: SGR - News) today signed landmark, multi-billion-dollar contracts with State Nuclear Power Technology Corporation Ltd. (SNPTC), Sanmen Nuclear Power Company Ltd, Shandong Nuclear Power Company Ltd., and China National Technical Import & Export Corporation (CNTIC) to provide four AP1000 nuclear power plants in China.
Specific terms were not disclosed, but the agreements are expected to generate or sustain no less than 5,000 U.S. jobs within Westinghouse, Shaw and suppliers in at least 20 states.
Westinghouse President and CEO Steve Tritch, who signed the contract on behalf of Westinghouse, said the contracts are highly significant for both the United States and China.
"The definitive contracts signed today will result in the first-ever deployment of advanced U.S. nuclear power technology in China," he said. "The plants will greatly increase China's ability to generate significant additional baseload electricity in a clean, safe and economical manner."
"The United States will benefit through the creation of thousands of well- paying jobs in both the design and engineering and traditional manufacturing segments of our economy. I want to emphasize, therefore, just how hard the United States government has worked to support Westinghouse in the development of the AP1000, and in assuring us an opportunity to compete for this rewarding and mutually beneficial business in China."
The comprehensive agreements signed today follow by five months the signing of framework agreements that confirmed the basic requirements and obligations of all parties involved. As a result of those earlier agreements, preliminary design, engineering and long-lead procurement work is already underway.
SNPTC announced in December, 2006 that it had selected the Westinghouse consortium and the AP1000 technology. Original bids for the four plants were submitted by Westinghouse and others competing for the project, in February, 2005.
The four plants are to be constructed in pairs at the Sanmen and Haiyang sites. Construction is expected to begin in 2009, with the first plant becoming operational in late 2013. The remaining three plants are expected to come on line in 2014 and 2015.
Westinghouse believes the AP1000 is ideally suited for the worldwide nuclear power marketplace. It has been selected as the technology of choice for no less than 12 advanced plants to be built in the United States over the next 10 to 12 years.
The AP1000 is attractive because it is:
-- the safest, most advanced, yet proven nuclear power plant currently
available in the worldwide marketplace
-- based on standard Westinghouse pressurized water reactor (PWR)
technology that has achieved more than 2,500 reactor years of highly
successful operation
-- an 1100MWe design that is ideal for providing baseload generating
capacity
-- modular in design, promoting ready standardization and high
construction quality
-- economical to construct and maintain (less concrete and steel and fewer
components and systems mean there is less to install, inspect and
maintain)
-- designed to promote ease of operation (features most advanced
instrumentation and control in the industry)
Westinghouse, a group company of Toshiba Corporation, is the world's pioneering nuclear power company and is a leading supplier of nuclear plant products and technologies to utilities throughout the world. Westinghouse, with Shaw, supplied the world's first PWR in 1957 in Shippingport, Pa. Today, Westinghouse technology is the basis for approximately one-half of the world's operating nuclear plants, including 60 percent of those in the United States.
--------------------------------------------------------------------------------
Source: Westinghouse Electric Company LLC
http://biz.yahoo.com/prnews/070724/netu024.html?.v=17
CHART WANTED: UITK.OB- anyone? tia...trying to compare the news here to the PR on the 19th...
afterhours: UITK.OB (.09) Ultitek Signs Airline Distribution Agreement With Tatarstan Airlines
Monday July 23, 4:01 pm ET
Shares Outstanding: 72.04M
ENGLEWOOD CLIFFS, NJ--(MARKET WIRE)--Jul 23, 2007 -- Ultitek Ltd. (OTC BB:UITK.OB - News) is pleased to announce that TAIS, Ultitek's wholly owned subsidiary, has come to terms with Tatarstan Airlines to provide airline distribution services to the airline. Tatarstan Airlines is an airline based in Kazan, Tatarstan, Russia. The airline has more than twenty aircraft and provides service to 30 domestic and some international cities. Among other features, an airline Global Distribution System (GDS) provides a booking interface between airlines and travel agencies.
"With the agreement we reached with Tatarstan Airlines added to the previously announced agreement with Air Astana, it can certainly be stated that we have jumped into the airline distribution with both feet. We anticipate more agreements in the near future," said Roman Price, CEO.
About Ultitek Ltd.
Through its wholly owned subsidiary, TAIS, Ultitek Ltd. has been a provider of Computerized Airline Reservations Systems software (CRS) since 1989. Today Ultitek Ltd. is the leader among reservations systems in the Russian Aviation market. In 2003, nine million passengers of 60 airlines were serviced by it, which consisted of more than 50% of the transport of passengers performed on domestic scheduled flights of carriers in Russia and the countries of the C.I.S.
SAFE HARBOR: The information in this news release includes certain forward-looking statements as defined in the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. The matters described in these forward-looking statements are based upon assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond Ultitek's control. Ultitek faces many risks that could cause its actual performance to differ materially from the results predicted by its forward-looking statements. Although Ultitek believes that the expectations reflected in forward-looking statements are reasonable, because of those risks, Ultitek's actual results, performance or achievements may differ materially from the results, performance or achievements contemplated by its forward-looking statements. Accordingly, it can give no assurance that the expectations of any of its forward-looking statements will prove to be correct. The information set forth in this news release represents management's current expectations and intentions. Ultitek assumes no responsibility to issue updates to the forward-looking matters discussed in this news release.
Contact:
Contact:
Ernest J. Sabato
Ultitek Ltd.
560 Sylvan Avenue
Englewood Cliffs, New Jersey 07632
Telephone: 1-201-541-1700 or 1-888-ULTITEK
Fax: 1-201-541-1778
Email address: ejs@ultitek.com
http://www.ultitek.com
--------------------------------------------------------------------------------
Source: Ultitek Ltd.
http://biz.yahoo.com/iw/070719/0279840.html
afterhours TNB: Thomas & Betts beats by $0.02; raises guidance for FY07 (TNB) 63.18 +0.76 : Reports Q2 (Jun) earnings of $0.80 per share, $0.02 better than the Reuters Estimates consensus of $0.78; revenues rose 8.4% year/year to $507.2 mln vs the $500.1 mln consensus. Co raises guidance for FY07, to EPS of $3.15-3.20 from $3.05-3.15 vs. $3.20 consensus.
http://finance.yahoo.com/q?s=tnb
Out for the rest of the afternoon. Cya and have fun. :)
they're stacking the bids now - they jump in on the bid, stack and remove them
GGBM at 4.17, lol. BTW: I DO notice my ticker faux pas in the header of that post. Thankfully a chart and a news clip corrected my entry for those who were interested in it's press.
(link back for press)
moving: CHINA (fri close at 9.40): CDC Factory Builds Industry Momentum with Record Software Licenses in Q2 2007
Monday July 23, 7:30 am ET
CDC Software's Manufacturing Operations Management Solution Selected by Leading Food Processors
HONG KONG & ATLANTA--(BUSINESS WIRE)--CDC Software, a wholly owned subsidiary of CDC Corporation (NASDAQ:CHINA - News) and a provider of industry-specific enterprise software applications and business services, announced today that during the second quarter of 2007, leading food manufacturers selected its recently launched CDC Factory solution to integrate factory scheduling, real-time performance management and analytics.
In the second quarter 2007, CDC Factory sales grew by more than 76% compared to prior best-quarter sales of the combined solutions. Also during the quarter, current customers of the solution, leveraging the measured success of their CDC Factory deployments, expanded their licenses to expand their deployments to additional factories.
"We are very pleased with the rapid growth in customer adoption of CDC Factory," said Eric Musser, CEO of CDC Software. "This accelerating demand from new customers and our feedback from current customers, in terms of measured impact on their businesses, is clear validation of our vision and strategy in the marketplace as vertical industry specialists. The process manufacturing industries are a strategic area of focus for us and we will continue to lead with innovative solutions that uniquely address key requirements and create measurable value."
CDC Factory is the first packaged manufacturing operations management solution that integrates finite factory scheduling, manufacturing execution systems (MES), real-time performance management, quality, maintenance and analytics processes so all users -- from shop floor operators to executive management -- can make real-time actionable decisions throughout the plant and across the enterprise. The solution is specifically designed to address the requirements of food and beverage, consumer products and pharmaceuticals manufacturers and is typically implemented and producing positive returns in 8 weeks or less. The solution is a tightly integrated combination of technologies from two of CDC Software's recently acquired companies, as well as internal R&D investments.
According to a recent AMR Research article, "With the introduction of CDC Factory, CDC Software sets a new bar for ERP providers with manufacturing aspirations. It now offers a highly usable, comprehensive suite of manufacturing operations abilities that are purpose-built for the specific needs of food, beverage, and consumer products (CP) companies that aren't planning to extend their general purpose ERP systems down into the shop-floor environment. It also provides arguably more prepackaged manufacturing operations functionality -- finite capacity scheduling, maintenance management, quality management, and operations intelligence functionality, specifically -- than the majority of best-of-breed MES products available for manufacturers in CDC's target markets." The article further states, "CDC Factory throws a curve ball at a market that's been perpetuating aging manufacturing application silos and lacking innovative business models."
New customers of CDC Factory in Q2 2007 included Windsor Foods, American Popcorn Company and Bay Valley Foods. Windsor Foods, a leading manufacturer of frozen ethnic foods and appetizers, is expecting its plant-wide implementation of CDC Factory to save it several hundred thousand dollars per year by delivering significant percentage-point improvements in the key areas of labor utilization, materials and packaging waste and administration time. The initial CDC Factory implementation will take place at Windsor's manufacturing facility in Toluca, Ill., with potential subsequent rollouts to the company's other eight sites over the next 18 months.
Windsor Foods' recent acquisitions, including that of Specialty Brands in 2004, had effectively doubled the size of the company. After a period of consolidation, the company's focus turned to a drive for increased profitability in an extremely competitive market space, further challenged by increasingly unfavorable commodities pricing. To achieve this goal, Windsor Foods required a detailed view of its manufacturing performance to identify the greatest opportunities for improvement and a systematic method of unlocking those benefits. Existing methods of collecting production data could not provide that information or the required methodology.
"After a detailed evaluation of nine vendors, we selected CDC Factory," said Steve Leins, vice president, Operations for Windsor. "CDC Factory stood out from the beginning because it offered a full end-to-end solution versus a single point solution. It also includes the most usable interface in our opinion, and 'out-of-the-box' functionality. The 3-day performance review conducted by CDC Software lets us see a working prototype of the product, in our setting, with data directly from our factory floor. This experience gave us a great baseline to know exactly which areas we will target first for immediate improvements. Another important decision point for us was the fact that the CDC team recognized the need to manage the culture change that a project like this facilitates. No other vendor had a method for managing this change."
"CDC Factory is a truly unique solution in the marketplace and rapidly gaining momentum as process manufacturers learn what can be accomplished with this new class of packaged applications for manufacturing operations management," said Mark Sutcliffe, general manager of CDC Factory. "We are also excited to see several multi-plant manufacturers adopting CDC Factory as part of their enterprise-wide strategy. As we have been doing with all of our customers, we look forward to working closely with these new customers to ensure their rapid deployments and successful attainment of their targeted operational improvements."
About CDC Factory
CDC Factory is the first packaged manufacturing operations management system that transforms manufacturing performance by empowering people to make real-time actionable decisions. By standardizing the best practices of lean manufacturing, OEE (Overall Equipment Effectiveness) and continuous improvement, CDC Factory provides a real-time framework that integrates scheduling, operations, quality and maintenance. Specifically designed for food and beverage, pharmaceutical packaging and consumer packaged goods manufacturers, CDC Factory enables real-time decision making to support a demand-driven strategy at all levels in the organization, from factory floor operators to executive management. Leading manufacturers are using CDC Factory to reduce operating costs and waste, unlock hidden capacity, improve customer service and employee satisfaction, while minimizing risk by assuring regulatory compliance. For more information, visit: www.cdcfactory.com.
About CDC Software
CDC Software, The Customer-Driven Company(TM), is a provider of enterprise software applications designed to help organizations deliver a superior customer experience while increasing efficiencies and profitability. CDC Software's product suite includes: CDC Factory (manufacturing operations management), Ross ERP (enterprise resource planning) and SCM (supply chain management), IMI warehouse management and order management, Pivotal CRM and Saratoga CRM (customer relationship management), Respond (customer complaint and feedback management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Platinum HRM (human resources) and business analytics solutions.
These industry-specific solutions are used by more than 6,000 customers worldwide within the manufacturing, financial services, health care, home building, real estate, and wholesale and retail distribution industries. The company completes its offerings with a full continuum of services that span the life cycle of technology and software applications, including implementation, project consulting, outsourced business services, application management and offshore development. CDC Software is the enterprise software unit of CDC Corporation (NASDAQ:CHINA - News) and is ranked number 12 on the Manufacturing Business Technology 2007 Global 100 List of Enterprise and Supply Chain Management Application vendors. For more information, please visit www.cdcsoftware.com.
About CDC Corporation
The CDC family of companies includes CDC Software focused on enterprise software applications and services, CDC Mobile focused on mobile applications, CDC Games focused on online games, and China.com focused on portals for the greater China markets. For more information about CDC Corporation (NASDAQ:CHINA - News), please visit www.cdccorporation.net.
Cautionary Note Regarding Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, including statements relating to CDC Factory, reducing waste, reducing overhead costs, increasing overall equipment effectiveness, and increase the number of units produced per man-hour and other statements that are not historical fact, the achievement of which involve risks, uncertainties and assumptions. These statements are based on management's current expectations and are subject to risks and uncertainties and changes in circumstances. There are important factors that could cause actual results to differ materially from those anticipated in the forward looking statements including, among others: the conditions of the process manufacturing industry; the continued ability of CDC Factory solutions to address industry-specific requirements of companies in the process manufacturing industry; demand for and market acceptance of new and existing CDC Factory solutions; development of new functionalities which would allow process manufacturers to compete more effectively and changes in the type of information required to compete in the process manufacturing industry. Further information on risks or other factors that could cause results to differ is detailed in filings or submissions with the United States Securities and Exchange Commission made by CDC Corporation in its Annual Report for the year ended December 31, 2006 on Form 20-F filed on July 2, 2007. All forward-looking statements included in this press release are based upon information available to management as of the date of the press release, and you are cautioned not to place undue reliance on any forward looking statements which speak only as of the date of this press release. The company assumes no obligation to update or alter the forward looking statements whether as a result of new information, future events or otherwise.
Contact:
CDC Corporation
Investor Relations
Monish Bahl, 678-259-8510
mbahl@cdcsoftware.com
or
CDC Software
Public Relations
Lorretta Gasper, 678-259-8631
lgasper@cdcsoftware.com
--------------------------------------------------------------------------------
Source: CDC Corporation
http://biz.yahoo.com/bw/070723/20070723005288.html?.v=1
thank you :)
CNCA.OB (thinly traded, nice news) 7.85: HollySys Announced Today the Signing of $115.8 Million in New Contracts
Monday July 23, 8:25 am ET
Shares Outstanding: 7.00M
Float: 6.33M
SAN DIEGO & BEIJING--(BUSINESS WIRE)--Chardan North China Acquisition Corp. (OTCBB: CNCA - News, CNCAU - News, CNCAW - News; "Chardan North" or "the Company"), announced today that its proposed business combination target, Gifted Time Holdings Limited and its operating subsidiaries, Beijing HollySys Company, Limited and Hangzhou HollySys Automation, Limited (collectively referred to as "HollySys") had signed a series of new contracts for large control systems to the power generation and rail industries totaling US $115.8 million from April 1, 2007 to July 15, 2007. The bulk of the revenues from these projects will be recognized over the next three years. These projects include:
A system upgrade for the Dayawan nuclear power plant
A new Control System for the Hening Line Railway
An integrated rail control system for Ningmei Mandarin Duck Lake Diggings
A subway control system for Shenzhen Subway Line 1
Dr. Wang Changli, Founder and CEO of HollySys, stated, "We are pleased to announce these contract signings as they demonstrate the value of all of the intellectual property that we have amassed over the years in designing control systems for the nuclear power and rail industries. These contract wins are proof that we have produced products highly valued by our clients and we anticipate that these contracts only represent the beginning of an increasing presence for us in these industries.
HollySys is one of only five approved suppliers of control systems to the rail industry, and the only approved domestic supplier of automation control systems to the nuclear power industry. Due to safety concerns, these are highly regulated industries and as an early market entrant in China and as the largest local player, HollySys has set the de facto automation standards for most of these industries. We look forward with confidence to our short-term and long-term future as a publicly listed company in the United States."
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, about Chardan North, HollySys and their combined business after completion of the proposed acquisition. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of Chardan North's and HollySys' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: business conditions in China; continued compliance with government regulations; legislation or regulatory environments, requirements or changes adversely affecting the businesses in which HollySys is engaged; cessation or changes in government incentive programs: potential trade barriers affecting international expansion; fluctuations in customer demand; management of rapid growth and transitions to new markets; intensity of competition from or introduction of new and superior products by other providers of automation and control system technology; timing, approval and market acceptance of new product introductions; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Chardan North's filings with the Securities and Exchange Commission, and the registration statement on Form S-4 , as amended (Reg. No. 333-132826). The information set forth herein should be read in light of such risks. Neither Chardan North nor HollySys assumes any obligation to update the information contained in this press release.
In connection with the pending transaction, HLS Systems International Ltd. ("HLS Systems") has filed with the SEC a Registration Statement on Form S-4 containing a Proxy Statement/Prospectus for the stockholders of Chardan North. The stockholders of Chardan North are urged to read the Registration Statement and the Proxy Statement/Prospectus, when it is available, as well as all other relevant documents filed or to be filed with the SEC, because they will contain important information about HollySys, HLS Systems, Chardan North and the proposed transaction. The final Proxy Statement/Prospectus will be mailed to stockholders of Chardan North after the Registration Statement is declared effective by the SEC. Chardan North stockholders will be able to obtain the Registration Statement, the Proxy Statement/Prospectus and any other relevant filed documents for free at the SEC's website (www.sec.gov). These documents can also be obtained for free from Chardan North by directing a request to Lori Johnson c/o Chardan Capital, 625 Broadway, Suite 1111, San Diego, CA 92101.
HLS Systems, Chardan North and their respective directors and officers may be deemed to be participants in the solicitation of approvals from Chardan North stockholders in respect of the proposed transaction. Information regarding Chardan North's participants will be available in the Proxy Statement /Prospectus. Additional information regarding the interests of such participants will be included in the Registration Statement containing the Proxy Statement / Prospectus.
Contact:
Chardan North China Acquisition Corp.
Richard Propper, MD
Chairman
619-795-4627
or
Investor Relations Counsel:
The Equity Group Inc.
Adam Prior
212-836-9606
aprior@equityny.com
--------------------------------------------------------------------------------
Source: Chardan North China Acquisition Corp.
http://biz.yahoo.com/bw/070723/20070723005660.html?.v=1
PLRS.OB .087 Pluristem's PLX Cells Show Promise in Treating Limb Ischemia
Monday July 23, 8:00 am ET
Revascularization Possible After PLX Therapy
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News; DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that favorable results have been obtained in pre-clinical testing using the Company's proprietary PLX cells to treat limb ischemia, a potential market of over $1 Billion.
Mr. Zami Aberman, Pluristem Chairman and CEO commented, "These results are encouraging and suggest that our PLX cells may be the first allogeneic, off-the-shelf product to treat this serious disease." PLX cells are placenta derived mesenchymal stem cells expanded in the Company's proprietary PluriX(TM) 3-D bioreactor system.
Scientists administered Pluristem's proprietary PLX cells in vivo to one set of ischemic mice. Post-treatment evaluation using Doppler technology indicated revascularization of the limb treated with PLX cells but not in those that were not treated with PLX. The hind legs of mice were rendered ischemic using standard industry methodologies.
Industry experts have estimated that therapeutics used in the treatment of limb ischemia market is over $1 Billion. However, current therapeutic methodologies have proven ineffective for many severe limb ischemic situations and led the medical community to call for the development of cellular therapies, such as Pluristem's PLX cells and other methods as alternative treatments.
About Limb Ischemia
In the US alone, it is estimated that 8-12 million people suffer from limb ischemia. The disease is characterized by narrowing and hardening of the arteries in the patient's limb(s) and caused and/or aggravated by diabetes, Buerger's Disease, other diseases and smoking. With decreased blood flow to the affected extremity, patients can suffer a host of complications including nerve and tissue damage. In advanced stages, limb ischemia can lead to gangrene which often requires treatment with amputation. The disease is associated with a high rate of mortality and the need for frequent hospitalization from surgical complications.
About Pluristem
Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB). Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel. www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that PLX Cells Shows Promise in Treating Limb Ischemia a potential market of over $1 Billion; that the Pluristem's cells can potentially result in beneficial therapies for a number of serious diseases and that the Company's PLX cells may be useful for treating or causing revascularization in the disease of limb ischemia; that These results are encouraging and suggest that our PLX cells may be the first allogeneic, off-the-shelf product to treat this serious disease. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Contact:
Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
or
Segue Ventures LLC
Craig Bird, 215-885-4981
CHBird@segue.biz
or
Investors' Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
--------------------------------------------------------------------------------
Source: Pluristem Life Systems, Inc.
http://biz.yahoo.com/bw/070723/20070723005626.html?.v=1
gm Clarity!
nice catch, liz
CERS: 6.28 Grifols S.A. and Cerus Corporation Agree to Commercialize the INTERCEPT Blood System in Spain and Portugal
Monday July 23, 5:50 am ET
Both Companies Are Dedicated to Establishing a Higher Standard for the Safety of Spanish and Portuguese Blood Transfusions
Shares Outstanding: 31.80M
Float: 26.57M
BARCELONA, Spain & CONCORD, Calif.--(BUSINESS WIRE)--Grifols S.A. (MCE: GRF) and Cerus Corporation (NASDAQ: CERS - News) today announced that the two companies have entered into an agreement to commercialize Cerus' INTERCEPT Blood System in Spain and Portugal. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens. More than 200,000 platelet units and 300,000 plasma units for transfusion are collected annually in Spain and Portugal.
ADVERTISEMENT
Under terms of the agreement, Grifols and Cerus will sell, deploy and support the INTERCEPT Blood System in Spanish and Portuguese blood centers. In addition, Grifols will be responsible for servicing the INTERCEPT system illuminators and will manage the supply chain for the INTERCEPT system through its distribution sites in Spain and Portugal.
"We are pleased to partner with Grifols, one of the largest pharmaceutical companies in Spain and the largest European plasma fractionator," said Claes Glassell, president and chief executive officer of Cerus Corporation. "The two companies are committed to enhancing the safety of the blood supply in Spain and Portugal by using the most advanced technology to reduce the risk of transfusion-transmitted diseases."
The INTERCEPT Blood System
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens, such as viruses, bacteria, and parasites that may be present in donated blood intended for transfusion. The system inactivates pathogens in platelets and plasma using the same illumination device, process and active compound. The INTERCEPT Blood System has received CE mark approvals in Europe for both the platelet and plasma systems. A Phase I clinical trial of the INTERCEPT Blood System for red cells has been completed in the United States.
ABOUT CERUS
Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy designed to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology. The system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in the research and development of prophylactic and therapeutic vaccines for infectious diseases.
INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.
ABOUT GRIFOLS
Grifols is a Spanish holding company specialized in the hospital pharmaceutical sector. Currently present in 90 countries, it is the leading European company in the hemoderivative market and the third largest producer in the world. In the coming years Grifols will strengthen its leadership position in the industry as a vertically integrated company, as a result of investments already undertaken. Grifols has a steady and assured supply of plasma and its fractionation capacity will allow the company to meet growing demand, principally in the United States market where the company intends to increase its presence.
Grifols' activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. For more than 60 years Grifols has developed, manufactured and marketed products of proven efficacy, quality and safety contributing to improve human health.
Contact:
Cerus U.S.
Myesha Edwards
Corporate Communications & Investor Relations
Cerus Corporation
(925) 288-6017
or
Cerus Spain
Alfonso Lopez
FIPRA International
+34 91 432 45 70
a.lopez@retionline.es
or
Grifols
Raquel Lumbreras / Alejandro Boza
Corporate Communications
Grifols S.A.
+34 91 311 92 90
--------------------------------------------------------------------------------
Source: Cerus Corporation
http://biz.yahoo.com/bw/070723/20070723005540.html?.v=1
TASR: Wow, there she goes again....TASER beats by 2 cents, beats handily on top line (TASR) 17.14 : Reports Q2 (Jun) earnings of $0.06 per share, $0.02 better than the Reuters Estimates consensus of $0.04; revenues rose 59.9% year/year to $25.9 mln vs the $21.3 mln consensus. "The second quarter results, with the highest quarterly revenues in our Company's history, have provided us with significant momentum as we move into the second half of 2007..."
http://finance.yahoo.com/q?s=tasr&d=t
ICFI 21.26 International Awarded EPA Contract Valued Up to $37 Million
Monday July 23, 7:00 am ET
Firm to Support Agency Efforts to Assess and Address Global Climate Change
Shares Outstanding: 14.14M
Float: 12.83M
FAIRFAX, Va.--(BUSINESS WIRE)--ICF International (NASDAQ:ICFI - News) today announced it won a new Indefinite Delivery/Indefinite Quantity contract with the U.S. Environmental Protection Agency (EPA) valued up to US$37 million over five years. Under the multiple-award contract, ICF will provide technical and outreach support services to the EPA for domestic and global climate change initiatives. This contract replaces two smaller ICF contracts. The capacity of this contract is nearly double the amount of the work done under the prior contracts. The company was awarded the contract vehicle through its subsidiary, ICF Incorporated, LLC.
"Interest in climate change has soared recently in the United States, and we expect EPA's policies and programs to expand and evolve rapidly over the next five years," said Randall Freed, an ICF senior vice president and climate change expert. "With increased interest in controlling the emissions of greenhouse gases, ICF International is poised to help EPA tackle this global challenge by offering expertise in the deployment of clean technologies across all sources and sinks of these gases."
"U.S. involvement with international programs will become increasingly important, and we can offer lessons for domestic policy that we've learned through our project work for clients in Europe, Canada, and other countries that have developed climate change policies," said Diana Pape, an ICF vice president and expert in greenhouse gas mitigation.
ICF has supported the EPA on climate change issues continuously since 1981. In addition to this contract, the firm holds five other large prime contracts with the agency on the full range of climate change issues. Additionally, the firm has more than 230 staff working on these issues in support of the following clients:
National governments in more than 50 countries, including the United States, United Kingdom, Ireland, Canada, Russia, and Ukraine;
Financial institutions in the United States and Europe, as well as development banks;
Leading companies, including more than 60 of the Financial Times' FT Global 500 and low-carbon technology suppliers.
ICF International (NASDAQ:ICFI - News) partners with government and commercial clients to deliver consulting services and technology solutions in the energy, climate change, environment, transportation, social programs, health, defense, and emergency management markets. The firm combines passion for its work with industry expertise and innovative analytics to produce compelling results throughout the entire program life cycle, from analysis and design through implementation and improvement. Since 1969, ICF has been serving government at all levels, major corporations, and multilateral institutions. More than 2,500 employees serve these clients worldwide. ICF's Web site is www.icfi.com.
This document may contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995--that is, statements related to future--not past--events, plans, and prospects. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "guidance," "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "seek," "should," "will," "would," or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial position, or state other forward-looking information, and are subject to factors that could cause actual results to differ materially from those anticipated. For ICF, particular uncertainties that could adversely or positively affect the Company's future results include but are not limited to: risks related to the government contracting industry, including the timely approval of government budgets, changes in client spending priorities, and the results of government audits and investigations; risks related to our business, including our dependence on contracts with U.S. Federal Government agencies and departments and the State of Louisiana; continued good relations with these and other customers; success in competitive bidding on recompete and new contracts; performance by ICF and its subcontractors under our contract with the State of Louisiana, Office of Community Development, including but not limited to the risks of failure to achieve certain levels of program activities, termination, or material modification of the contract, and political uncertainties relating to The Road Home program; uncertainties as to whether revenues corresponding to the Company's contract backlog will actually be received; the future of the energy sector of the global economy; our ability to attract and retain management and staff; strategic actions, including attempts to expand our service offerings and client base, the ability to make acquisitions, and the performance and future integration of acquired businesses; risks associated with operations outside the United States, including but not limited to international, regional, and national economic conditions, including the effects of terrorist activities, war, and currency fluctuations; and other risks and uncertainties disclosed in the Company's filings with the Securities and Exchange Commission. These uncertainties may cause ICF's actual future results to be materially different than those expressed in the Company's forward-looking statements. ICF does not undertake to update its forward-looking statements.
Contact:
ICF International
Media contact:
Polly Shannon, 703-934-3144
pshannon@icfi.com
--------------------------------------------------------------------------------
Source: ICF International
http://biz.yahoo.com/bw/070723/20070723005204.html?.v=1
GM :)
yikes!! PDPR in the WRONG business to include this in their PR:
"You know, becoming fully reporting is akin to having a child. Starting one is always fun, and then the work begins. ...
http://biz.yahoo.com/bw/070723/20070723005408.html?.v=1
NPDI.OB 0.45 (*note, thin trade/check bottom of post for charts): 0.45 Neptune Industries, Inc. Announces Record Fourth Quarter Revenues
Monday July 23, 7:00 am ET
BOCA RATON, FL--(MARKET WIRE)--Jul 23, 2007 -- Neptune Industries, Inc. (OTC BB:NPDI.OB - News) announced today that its Blue Heron Aqua Farms, LLC. subsidiary set a new record for fourth quarter sales. Revenues increased more than 200% from the fourth quarter last year, and annual revenues at the close of the fiscal year, 6/30/07, were up a record 56% from 2006.
Mr. Sal Cherch, Chief Operating Officer, stated, "It is gratifying that the technology and production methodology being applied at Blue Heron have led to consistently increasing sales and product acceptance. Demand from our current customer base continues to exceed production capabilities. We are in the initial stages of addressing this issue through our current expansion and acquisition plans."
Based in Boca Raton, Florida, Neptune Industries, Inc. has developed a scalable, modular aquaculture technology called Aqua-Sphere(TM) and Aqua-Cell(TM) that successfully address the environmental concerns of most aquaculture operations by controlling and recycling all waste products, while insuring the production of the highest quality fish at an affordable price. The company currently operates the Blue Heron Aqua Farms in Florida City, FL and is a leading producer of hybrid striped bass, which it markets internationally as Everglades Striped Bass(TM). The company's current production at its Blue Heron farm, and future production with Aqua-Sphere(TM) System technology are intended to target the organic market as soon as organic certification of farm-raised seafood becomes available. The Company is also in development of an advanced dietary nutritional component called Ento-Protein(TM). Ento-Protein(TM) is a high quality sustainable protein derived from insects, and is intended to be a replacement for the scarce fish meal now used in fish and animal diets. For further information, please visit the Company's website at: www.neptuneindustries.net
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
Contact:
Investor Relations Contact:
Michael Steinberg
Chelsea Holdings, Inc.
1200 S. Federal Hwy., Suite 200
Boca Raton, FL 33431
561-210-8544
Email: info@neptuneindustries.net
--------------------------------------------------------------------------------
Source: Neptune Industries, Inc.
http://biz.yahoo.com/iw/070723/0281084.html
EPCT: 2.15- EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Monday July 23, 12:01 am ET
Shares Outstanding6: 32.40M
Float: 20.61M
TARRYTOWN, N.Y., July 23 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will study EpiCept(TM) NP-1, its patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, for the treatment of chemotherapy induced peripheral neuropathy (CPN) in the ATTRACT-CPN Phase III Study (Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy). The study will be conducted within a network of approximately 25 sites under the direction of the National Cancer Institute (NCI) funded Community Clinical Oncology Program (CCOP).
ADVERTISEMENT
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO)
Peripheral neuropathy, a painful condition caused by damage to the nerves in the peripheral nervous system, affects over 15 million people in the United States. CPN is the result of the toxicity of a number chemotherapeutic agents. The risk of neuropathy increases with cumulative exposure. The first symptoms are paresthesias, with dysesthesias occurring after a few courses of chemotherapy, and often followed by severe neuropathic pain.
The Study Chair, Professor Robert H. Dworkin stated, "I am pleased that EpiCept and the CCOP are working together to address this unmet medical need. CPN is becoming a more prevalent issue with the wider use of more active chemotherapeutic agents."
"We are excited that the NCI funded CCOP has chosen to conduct this clinical trial of EpiCept NP-1," remarked Jack Talley, President and Chief Executive Officer. "We believe the results of this study will build upon the body of clinical evidence which demonstrates the ability of NP-1 to provide long-term relief from the pain resulting from peripheral neuropathies."
The topical delivery mechanism of EpiCept NP-1 could provide important clinical advantages in treating CPN patients, including the reduction of systemic side effects and drug interactions.
The Phase III trial is expected to be initiated before the end of the third quarter of 2007. The double-blind, randomized placebo-controlled study will enroll approximately 400 patients suffering from painful CPN for at least 28 days following the conclusion of chemotherapy.
The trial will be 12 weeks in duration, with the primary endpoint being the change in average daily pain intensity scores from baseline to the end point. The secondary endpoints include the percentage of patients whose pain intensity decreases greater or equal to 30% from baseline and various other measures.
EpiCept NP-1 Clinical Development
EpiCept has initiated two additional Phase IIb trials for EpiCept NP-1, enrolling a total of 700 patients. The first trial is a 200 patient, placebo- controlled study of NP-1 in patients with diabetic peripheral neuropathy (DPN). More patients suffer from DPN than any other type of neuropathic pain. Only two medications are currently approved for this use. The trial is intended to confirm and expand upon earlier work which provided an efficacy signal in this type of neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four-week duration of the trial. Preliminary results are expected by the fourth quarter of 2007.
The second trial is a 500 patient, placebo- and active-controlled trial in peripheral herpetic neuropathy (PHN). This trial will compare the efficacy and safety of NP-1 vs. gabapentin as well as placebo. This active comparator trial is one of the first such efforts to examine any candidate compound at this scale in neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four-week duration of trial. Preliminary results are expected in the first quarter of 2008.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is under review by the European Agency for the Evaluation of Medicinal Products (EMEA). EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP- 1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to have our common stock readmitted to trading on The Nasdaq Global Market; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.
EPCT-GEN
--------------------------------------------------------------------------------
Source: EpiCept Corporation
http://biz.yahoo.com/prnews/070723/nym012.html?.v=101